1. Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
   Yuhao Ye et al, 2023, Biomedicine & Pharmacotherapy CrossRef
2. Potassium Ion Channels in Malignant Central Nervous System Cancers
   Yasmin Boyle et al, 2022, Cancers CrossRef
3. Refinement of computational identification of somatic copy number alterations using DNA methylation microarrays illustrated in cancers of unknown primary
   Pedro Blecua et al, 2022, Briefings in Bioinformatics CrossRef
4. Adult adrenal neuroblastoma: A case report
   Shenghan Xu et al, 2021, Molecular and Clinical Oncology CrossRef
5. PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
   Aryana R. Rasti et al, 2022, JCO Precision Oncology CrossRef
6. Non-uniformity in in vitro drug-induced cytotoxicity as evidenced by differences in IC50 values – implications and way forward
   T. Arokia Femina et al, 2023, Journal of Pharmacological and Toxicological Methods CrossRef
7. Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
   Julian S. Rechberger et al, 2023, Diagnostics CrossRef
8. Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
   Monika Lukoseviciute et al, 2023, Oncology Reports CrossRef
9. Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents
   Vincent Montero et al, 2024, European Journal of Medicinal Chemistry CrossRef
10. Advances in pharmacotherapy for neuroblastoma
    Parmida Sadat Pezeshki et al, 2021, Expert Opinion on Pharmacotherapy CrossRef
11. The quest to develop an effective therapy for neuroblastoma
    Praveen Bhoopathi et al, 2021, Journal of Cellular Physiology CrossRef
12. Targeting FGFR for cancer therapy
    Pei Zhang et al, 2024, Journal of Hematology & Oncology CrossRef
13. Sodium Butylated Hydroxytoluene: A Functional Group Tolerant, Eco‐Friendly Base for Solvent‐Free, Pd‐Catalysed Amination
    Volodymyr Semeniuchenko et al, 2021, Chemistry – A European Journal CrossRef
14. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma
    Francesca Musumeci et al, 2021, Molecules CrossRef
15. Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model
    Monika Lukoseviciute et al, 2024, Biomedicine & Pharmacotherapy CrossRef
16. Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
    Monika Lukoseviciute et al, 2021, Frontiers in Oncology CrossRef
17. Comprehending fibroblast growth factor receptor like 1: Oncogene or tumor suppressor?
    null Aprajita et al, 2021, Cancer Treatment and Research Communications CrossRef
18. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario
    Marina Ferreira Candido et al, 2023, Pharmaceutics CrossRef